Whitfield Represents CF PharmTech on its HK$300 Million H-Share Placing
Overview
CF PharmTech completed an H-share placement on August 6, 2026, after its July 31 announcement, according to the source.
Proceeds and coordinators
The offering generated approximately HK$300 million gross. CLSA and CCB International Capital were among the overall coordinators.
Development funding
The company planned to fund drug research, clinical studies, inhaled-product formulation, delivery-device work and regulatory applications, rather than a single identified acquisition.
Named advisers
Mengyu Lu, George Zheng, Yuchen Han and Jiawei Zhao are the capital markets advisers credited. The source also links the mandate with CF PharmTech's October 2025 IPO.
